

March 12, 2015



SCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit

RESEARCH TRIANGLE PARK, N.C., March 12, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that members of the SCYNEXIS executive management team will present at the Jefferies 2015 Antibiotic Summit hosted by Eun Yang at the Jefferies Offices in New York City on Wednesday, March 18, 2015, at 2:10 p.m. ET.

About SCYNEXIS, Inc.

SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.

CONTACT: Company
Chuck Osborne
Chief Financial Officer
Tel: 919-544-8600
E-mail: chuck.osborne@scynexis.com

Investor Relations
Jillian Connell
The Trout Group
Tel: 646-378-2956
Email: jconnell@troutgroup.com

Media Relations
Heather Savelle
MacDougall Biomedical Communications
Tel: 781-235-3060
E-mail: hsavelle@macbiocom.com

Source: SCYNEXIS, Inc.